Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property
24 janv. 2022 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study
19 janv. 2022 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study
14 janv. 2022 08h15 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Jan. 14, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Issues Compensation Options
04 janv. 2022 09h15 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2
08 déc. 2021 07h04 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial
02 déc. 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces New Chief Financial Officer
30 nov. 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study
24 nov. 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces Effective Date of Previously Announced Share Consolidation
23 nov. 2021 16h01 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (“Algernon” or the “Company”) (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF), a clinical stage pharmaceutical...
Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study
19 nov. 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) a clinical stage pharmaceutical...